{
  "id": 4653742,
  "title": "Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances",
  "url": "https://urgent.news/2026/08/31/earnings-call-transcript-biolinerx-q2-2026-revenue-flat-as-glix1",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-31T14:18:20.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-biolinerx-q2-2026-revenue-flat-as-glix1-advances-93CH-4882976"
  },
  "original_language": "en",
  "account": "BioLineRx disclosed its second-quarter 2026 financials, revealing flat revenue at $0.3 million and a widening net loss of $4.3 million. The company's lead drug, GLIX1, an oral small molecule for glioblastoma, showed promising safety data and expanding enrollment in early-stage trials at NYU Langone Health, Northwestern University, and Moffitt Cancer Center. GLIX1's favorable profile includes no reliance on the immune system and a clean safety profile in animal studies. The company's cash position, $13.1 million, should cover operations through the first half of 2027, with a planned offering raising $3.75 million. Analysts suggest the stock may be undervalued at $2.675, with a fair value estimate exceeding the current price. BioLineRx's focus on GLIX1, along with its financial challenges, will likely continue to drive investor interest.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Credo Technology Earnings Preview: $600M optical revenue ramp in focus",
        "url": "https://urgent.news/2026/08/31/credo-technology-earnings-preview-600m-optical-revenue-ramp-in-focus",
        "published": "2026-08-31T14:11:55.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}